Impacto da imunização contra o papilomavírus humano na prevenção do câncer do colo do útero: uma revisão integrativa / Impact of immunization against human papillomavirus in the prevention of cervical cancer: an integrative review / Impacto de la inmunización contra el virus del papiloma humano en la prevención del cáncer de cuello uterino: una revisión integradora

Esta revisão integrativa teve como objetivo identificar na literatura a produção científica que estabeleça uma relação entre a vacinação contra o HPV e a prevenção do câncer do colo uterino. No período entre 24 de março e 28 de abril de 2023, foi realizada a busca bibliográfica seguindo os critérios de inclusão: artigos publicados nos últimos cinco anos, em português, inglês ou espanhol e Qualis CAPES mínimo B2. Para alcançar os objetivos dessa revisão, foram selecionados artigos a partir da análise dos títulos, dos resumos e da leitura integral, excluindo em cada etapa os que não se enquadravam nos critérios pré-estabelecidos. Após busca na base de dados, foram localizados um total de 973 artigos, 58 na PubMed e 915 na Biblioteca Virtual em Saúde. Destes, apenas oito artigos atenderam a todos os critérios e foram incluídos na presente revisão. Os trabalhos incluídos foram publicados, entre os anos de 2018 e 2022, em periódicos internacionais. Existem diversas evidências da relação entre a vacinação contra o HPV e a prevenção do câncer de colo uterino. Porém, a taxa de adesão à vacina ainda é muito baixa, por mais que esta tenha um papel fundamental na prevenção do câncer cervical, bem como na prevenção do câncer de pênis, anal e orofaríngeo e outras infecções pelo HPV.

This integrative review aimed to identify in the literature the scientific production that establishes a relationship between the immunization against HPV and the prevention of cervical cancer. In the period between 24 March and 28 April 2023 it was made a bibliography research following the inclusion criteria: articles published in the last five years, in Portuguese, English or Spanish, and Qualis CAPES minimum as B2. To reach this review goals, there were selected articles based on title analysis, summary and unabridged reading, excluding, in every stage, those that did not enter the preestablished criteria. After the research in the data base, there was found the total of 973 articles, 58 in PubMed and 915 in Virtual Health Library. Only eight articles met all criteria and were included in this review. All the articles included were published, between 2018 and 2022, in international periodicals. There is evidence of a link between HPV vaccination and the prevention to cervical cancer. However, the adhesion to the vaccine is still very low, even if it has a fundamental role in the prevention to cervical, penile, anal and oropharyngeal cancer, as well as in the prevention of other HPV infections.

Esta revisión integradora tuvo como objetivo identificar en la literatura la producción científica que establece una relación entre la inmunización contra el VPH y la prevención del cáncer de cuello uterino. En el período comprendido entre el 24 de marzo y el 28 de abril de 2023 se realizó una investigación bibliográfica siguiendo los criterios de inclusión: artículos publicados en los últimos cinco años, en portugués, inglés o español, y Qualis CAPES mínimo como B2. Para alcanzar los objetivos de esta revisión, se seleccionaron los artículos a partir del análisis del título, resumen y lectura íntegra, excluyendo, en cada etapa, aquellos que no entraban en los criterios preestablecidos. Después de la pesquisa en la base de datos, se encontró el total de 973 artículos, 58 en PubMed y 915 en la Biblioteca Virtual de Salud. Sólo ocho artículos cumplieron todos los criterios y fueron incluidos en esta revisión. Todos los artículos incluidos fueron publicados, entre 2018 y 2022, en publicaciones periódicas internacionales. Existen evidencias de la relación entre la vacunación frente al VPH y la prevención del cáncer de cuello de útero. Sin embargo, la adhesión a la vacuna es todavía muy baja, aunque tenga un papel fundamental en la prevención al cáncer de cuello uterino, pene, ano y orofaringe, así como en la prevención de otras infecciones por VPH.

Involvement of MT2 receptors in protective effects of melatonin against cisplatin-induced gastrointestinal damage in mice

Abstract Melatonin (MLT) reportedly reduces side effects associated with certain antineoplastic agents. Accordingly, we investigated the effect of MLT on cisplatin (CP)-induced gastric emptying (GE) delay. Mice were intraperitoneally pretreated with vehicle (ethanol 5%; control group), MLT (5, 10, or 20 mg/kg), or N-acetylcysteine (NAC; 150 mg/kg), followed by CP treatment (5 mg/kg). Pharmacological modulation was analyzed using relevant receptor antagonists (luzindole: non-selective MT1/MT2 antagonist; 5 mg/kg or 4-P-PDOT: selective MT2 antagonist; 4 mg/kg) before treatment with MLT plus CP. All treatments were performed once daily for three days. GE was assessed using phenol red. Gut morphology was examined using scanning electron microscopy and optical microscopy. Compared with the control, CP decreased GE. Pretreatment with NAC and MLT (5 and 10 mg/kg) did not prevent CP-induced gastric dysmotility; however, pretreatment with 20 mg/kg MLT prevented this effect. In addition, luzindole and 4-P-PDOT suppressed MLT-mediated gastroprotection against cytotoxic effects of CP. CP caused degeneration of the gut mucosa, which was attenuated by MLT treatment. Thus, 20 mg/kg MLT prevented the GE delay and decreased CP-induced adverse effects on the gut mucosa. In addition, the gastroprotective activity was mediated via the MT2 receptor.

Involvement of PTEN and FOXO3a Proteins in the Protective Activity of Protocatechuic Acid Against Cisplatin-Induced Ovarian Toxicity in Mice.

The present study evaluated the effects of protocatechuic acid (PCA) after cisplatin-induced ovarian toxicity in mice and if PTEN and FOXO3a proteins are involved in PCA action. The mice were divided into five experimental groups (five animals per group) and treated once a day for 3 days as follows: (1) the control group was pretreated with oral administration (o.p.) of saline solution, followed by an intraperitoneal (i.p.) injection of saline solution. The other groups were pretreated (o.p.) with (2) saline solution (cisplatin group), (3) N-acetylcysteine (150 mg/kg of body weight), or with (4) 20 or (5) 50 mg/kg body weight of PCA, followed by 5 mg/kg body weight (i.p.) of cisplatin. Next, the ovaries were destined to histological (morphology and activation), immunohistochemical (PCNA and cleaved caspase-3 expression), and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. Moreover, the immunoreactivity for p-PTEN and p-FOXO3a was evaluated to investigate a potential mechanism by which PCA could prevent the cisplatin-induced ovarian damage. Pretreatment with N-acetylcysteine or 20 mg/kg PCA before cisplatin preserved the percentage of normal follicles and cell proliferation as observed in the control, reduced apoptosis and ROS levels, and showed higher active mitochondria and GSH levels than the cisplatin treatment (P < 0.05). Moreover, pretreatment with 20 mg/kg PCA decreased cisplatin-induced p-PTEN and increased (P < 0.05) nuclear export of p-FOXO3a. In conclusion, PCA at 20 mg/kg reduced apoptosis, maintained cell proliferation and mitochondrial function, reduced ROS production, and increased GSH expression likely through the involvement of PTEN and FOXO3a proteins.

Supplemented powdered coconut water (ACP-406®) promotes growth of goat secondary follicles and oocyte meiotic resumption.

The objective of this study was to test the efficiency of powdered coconut water (ACP-406®) base-medium without or with the addition of supplements on in vitro culture of isolated goat secondary follicles. Follicles were cultured for 18 days in α-MEM or in ACP-406®, both without supplements (referred to as α-MEM and ACP, respectively), or both supplemented with BSA, insulin, transferrin, selenium, glutamine, hypoxanthine, and ascorbic acid (referred to as α-MEM+ and ACP+). Follicular morphology, antrum formation, follicular and oocyte diameter, levels of glutathione (GSH), and chromatin configuration after in vitro maturation were evaluated. At the end of culture, ACP-406® base-medium (without or with supplements) showed a higher (P < 0.05) percentage of normal follicles than α-MEM (without or with supplements). Antrum formation was similar among α-MEM+, ACP and ACP+, and significantly higher than α-MEM without supplements. The follicular diameter was greater in ACP+ than α-MEM, and similar to other treatments. Moreover, fully and daily grown rates were higher (P < 0.05) in ACP-406® base-medium (without or with supplements) than α-MEM (without or with supplements). Levels of GSH were similar between ACP+ and α-MEM+ treatments. Both ACP+ and α-MEM+ allowed meiotic resumption without a significant difference between the two groups. In conclusion, supplemented ACP-406® base-medium maintained follicular survival and promoted the development as well as meiotic resumption of isolated goat secondary follicles cultured in vitro for 18 days.